Kalos Therapeutics, Inc. accepted into CONNECT’s Get Coached to Get Capital program

Oct. 26, 2012 - PRLog -- SAN DIEGO ---Kalos Therapeutics, Inc. Kalos Therapeutics, Inc. is a biomedical company targeting diseases caused by an abnormally high growth rate of cells (hyperproliferation). Our initial therapeutic focus is on cancer with testing being done on therapeutic approaches to treating age-related macular degeneration (AMD), our strategy is to leverage the natural antiproliferative activity of the Atrial Natriuretic Peptide (ANP) family of peptides. Kalos has identified the motif in this family of peptides that is responsible for controlling cell growth (the anti-cell proliferation motif, or ACM), and is developing a new class of anti-proliferative drugs based on this motif. Kalos has recently been accepted into the new Get Coached to Get Capital program offered by CONNECT, a world-recognized, San Diego-based innovation accelerator. The program seeks out radical innovation in the Southern California start-up scene and offers coaching in preparation to give a high-profile presentation to investors.  

Kalos Therapeutics is one of 22 companies accepted into the program in the Life Sciences category out of a pool of about 50 applicants. The Life Sciences category focuses on companies specializing in instrumentation, diagnostics, bio-markers, microbiology, molecular biology, therapeutics, pharmaceuticals and other life sciences specialties.

George Colberg Co-founder of Kalos Therapeutics, Inc., commented, “Working with CONNECT is a wonderful opportunity for a Company to get investor ready and coached by recognized industry experts.”

The program will kick-off with intensive mentoring by CONNECT's world renown Springboard mentoring program that will help the company fine-tune its investor pitch before it presents to industry judges to vie for the opportunity to present to a series of investor showcases for angels, venture capital firms, corporate venture and licensing representatives and family foundations across California.

By participating in the program, Kalos will have also have access to networking with prominent connections in the industry, entrepreneur clinics and a collaborative workspace, provided by CONNECT.

Contact:

Kalos Therapeutics George Colberg, Executive Chairman 858-552-6890

Kalos Therapeutics, Inc.

info@kalostpx.com

For further information contact gcolberg@kalostpx.com or 858-552-6890

CONTACT: Kalos Therapeutics George Colberg, Executive Chairman 858-552-6890

North America, California

INDUSTRY KEYWORD: Cancer, Health, Biotechnology, Novel Therapies, Oncology, ARMD, Pharmaceutical, Research